Has Alyssa Shon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $12,428 in general payments to Alyssa Shon, MD across 12 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alyssa Shon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alyssa Shon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alyssa Shon, MD

Infectious Disease · Buffalo, NYNPI 1962609677

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,270 of the $12,428 with a category attached, or 90.7%. Every reported general payment came from a single manufacturer, Viiv Healthcare Company. Reporting peaked in 2019 at $5,925 and has fallen 98.9% since, to $63 in 2025. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,428in general payments, 2019–2025

Across 12 payments — averaging $1035.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Viiv Healthcare Company$12K

$294,457in research payments, 2019–2025

Across 76 payments — averaging $3874.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Viiv Healthcare Company$253K
Merck$42K

What the payments were for

Consulting fees$11,27091%
Travel & lodging$8977%
Food & beverage$2612%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Viiv Healthcare Company	12	$12,428

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CABENUVA$4,830
DOVATO$3,680

How this compares

$12,428 in reported general payments places this provider in the 90th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York →

Medicare billing

Part B allowed, 2024

$11,180

Medicare patients

Services billed

106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	366	$1,353,200
TivicayDolutegravir Sodium	138	$294,685
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf	46	$218,051
DovatoDolutegravir Sodium/Lamivudine	75	$213,574
TriumeqAbacavir/Dolutegravir/Lamivudi	52	$195,015
OdefseyEmtricitab/Rilpiviri/Tenof Ala	46	$158,608
PrezcobixDarunavir/Cobicistat	67	$153,620
GenvoyaElviteg/Cob/Emtri/Tenof Alafen	30	$108,515
DescovyEmtricitabine/Tenofov Alafenam	49	$105,123
CabenuvaCabotegravir/Rilpivirine	16	$87,195
JulucaDolutegravir/Rilpivirine	20	$70,611
OzempicSemaglutide	53	$49,516
JardianceEmpagliflozin	49	$31,361
TrulicityDulaglutide	22	$21,007
EliquisApixaban	28	$15,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Viiv Healthcare CompanyTivicay, Dovato, Triumeq, Cabenuva, Juluca	$12,428	$861,080301 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 799 infectious disease providers in New York.

Other infectious disease in Buffalo

Harish MoorjaniBriarcliff Manor$733K
Sorana Segal MaurerFlushing$598K
Sian JonesNew York$406K
Antonio UrbinaNew York$373K
David BekhorNew York$358K
Andre BrutusBrooklyn$303K
Stephen ThomasSyracuse$294K
Glenn TurettFlushing$253K
Genovefa PapanicolaouNew York$209K
Abhay DhandValhalla$201K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →